5-ó2-氯-4-(三氟甲烷)苯基-2-糠醛 | 306936-04-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-ó2-氯-4-(三氟甲烷)苯基-2-糠醛
• 中文别名: 5-[2-氯-4-(三氟甲基)苯基]-2-呋喃甲醛
• 英文名称: 5-(2-chloro-4-(trifluoromethyl)phenyl)furan-2-carbaldehyde
• 英文别名: 5-[2-chloro-4-(trifluoromethyl)phenyl]-2-furaldehyde；5-[2-chloro-4-(trifluoromethyl)phenyl]furan-2-carbaldehyde
• CAS: 306936-04-9
• 化学式: C₁₂H₆ClF₃O₂
• mdl: MFCD01571128
• 分子量: 274.627
• InChiKey: SAEPEPVLSICNRE-UHFFFAOYSA-N

物化性质

• 熔点：
  86 °C

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2932190090
• 安全说明：
  S26,S37/39

SDS

Name:	5-[2-Chloro-4-(trifluoromethyl)phenyl]-2-furaldehyde 97% Material Safety Data Sheet
Synonym:
CAS:	306936-04-9

Section 1 - Chemical Product MSDS Name:5-[2-Chloro-4-(trifluoromethyl)phenyl]-2-furaldehyde 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
306936-04-9	5-[2-Chloro-4-(trifluoromethyl)phenyl]	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.Air sensitive.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 306936-04-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 81 - 83 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H6ClF3O2
Molecular Weight: 275

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to air.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, carbon dioxide, hydrogen fluoride gas, acrid smoke and fumes, fluorine.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 306936-04-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-[2-Chloro-4-(trifluoromethyl)phenyl]-2-furaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 306936-04-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 306936-04-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 306936-04-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-ó2-氯-4-(三氟甲烷)苯基-2-糠醛 、 N-(3-piperidin-4-ylphenyl)isobutyramide 生成 N-{3-[1-({5-[2-chloro-4-(trifluoromethyl)phenyl]-2-furyl}methyl)-4-piperidinyl]phenyl}-2-methylpropanamide
  参考文献：
  名称：

  Substituted anilinic piperidines as MCH selective antagonists

  摘要：

  本发明涉及选择性拮抗黑色素浓集激素-1（MCH1）受体的化合物。本发明提供了一种药物组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明提供了一种由本发明化合物的治疗有效量和药学上可接受的载体组成的药物组合物。本发明还提供了一种制备药物组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体组合。

  公开号：

  US20070043080A1
• 作为产物：
  描述：

  5-碘-2-呋喃甲醛 、 3-氯-4-碘三氟甲苯 在 indium(III) chloride 、 三甲基氯硅烷 、 lithium chloride 、 锌 、 2-dicyclohexylphosphino-2’,6’-dimethoxybiphenyl 、 palladium diacetate 作用下， 以 四氢呋喃 为溶剂， 反应 1.25h， 以514 mg的产率得到5-ó2-氯-4-(三氟甲烷)苯基-2-糠醛
  参考文献：
  名称：

  通过InX3和LiCl催化的将锌插入芳基和杂芳基碘化物和溴化物中来制备多功能有机卤化锌

  摘要：

  由InCl 3（3 mol％）和LiCl（30 mol％）组成的催化体系可通过将锌粉插入THF中的各种芳基碘化物中，在50°C下以高达95％的产率方便地制备多官能芳基卤化锌。使用THF / DMPU（1：1）混合物可缩短反应速率，并允许制备酮基取代的芳基锌试剂。在In（acac）3（3 mol％）和LiCl（150 mol％）的存在下，锌顺利插入到各种芳基和杂芳基溴化物中（50°C，2-18 h）。在In（acac）3（10 mol％）和LiCl（150 mol％）存在下，烷基溴化物也转化为相应的锌试剂，产率为70-80％。

  DOI：

  10.1002/chem.201605139

文献信息

• Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries
  作者：Tobias J. Hauke、Thomas Wein、Georg Höfner、Klaus T. Wanner

  DOI：10.1021/acs.jmedchem.8b01602

  日期：2018.11.21

  study describes the screening of dynamic combinatorial libraries based on nipecotic acid as core structure with substituents attached to the 5- instead of the common 1-position for the search of novel inhibitors of the GABA transporter GAT1. The generated pseudostatic hydrazone libraries included a total of nearly 900 compounds and were screened for their binding affinities toward GAT1 in competitive mass

  这项研究描述了筛选以菊苣酸为核心结构的动态组合文库的筛选方法，该结构具有取代基附着在5位而不是常见的1位上，以寻找GABA转运蛋白GAT1的新型抑制剂。生成的伪静态文库总共包含近900种化合物，并在基于竞争质谱（MS）的结合试验中筛选了它们对GAT1的结合亲和力。最高亲和力的腙表征（与顺-构型外消旋- 16gf结合和吸收实验中带有一个5-（1-萘基）呋喃-2-基残基和一个最有效的四原子间隔基）揭示了GAT1的变构相互作用，迄今为止尚无关于其他任何尼克酸衍生物的报道。因此，本文引入的5-取代的庚酸衍生物可以用作研究由GAT1介导的变构调节的GABA转运的有价值的工具，并且还可以作为新一类GAT1抑制剂的起点。
• Generation and Screening of Oxime Libraries Addressing the Neuronal GABA Transporter GAT1
  作者：Felix T. Kern、Klaus T. Wanner

  DOI：10.1002/cmdc.201402376

  日期：2015.2

  present study was to transfer the concept of library screening by MS binding assays, so far applied to pseudostatic hydrazine libraries, to static oxime libraries to screen for new potent inhibitors of mGAT1, the most abundant GABA transporter in the central nervous system that represents a validated drug target for the treatment of epilepsy. Library generation was performed by reaction of guvacine derivatives

  本研究的目的是将到目前为止已应用于假静态肼文库的MS结合测定法转移文库筛选的概念，转移至静态肟文库中以筛选新型强效抑制剂mGAT1，mGAT1是中枢神经系统中最丰富的GABA转运蛋白。代表治疗癫痫病的有效药物靶标。文库的产生是通过将具有羟胺官能度的番石榴碱衍生物与各种四种醛进行反应来进行的。稀释后，通过竞争性MS结合测定法筛选文库。解卷积实验可以识别最活跃的文库中的命中，然后将它们重新合成以进行生物学评估。这样，鉴定出一系列显示结合亲和力≥8.00（p Ki）在mGAT1，在功能性GABA吸收试验中，其中一种是迄今为止已知最有效的mGAT1抑制剂，pIC 50值为8.27±0.03。
• MS‐Based Screening of 5‐Substituted Nipecotic Acid Derived Hydrazone Libraries as Ligands of the GABA Transporter 1
  作者：Tobias J. Hauke、Georg Höfner、Klaus T. Wanner

  DOI：10.1002/cmdc.201800729

  日期：——

  A screening of compound libraries based on nipecotic acid derivatives with lipophilic residues attached to the scarcely explored 5-position of the core structure was used for the search of new inhibitors of the γ-aminobutyric acid (GABA) transporter 1 (mGAT1). The generated compound libraries, which were based on hydrazone chemistry commonly used in dynamic combinatorial chemistry but rendered pseudostatic

  筛选基于带有亲脂性残基的嗜油菌酸衍生物的化合物文库，该亲脂性残基附着在核心结构的很少探索的5位上，用于寻找γ-氨基丁酸（GABA）转运蛋白1（mGAT1）的新抑制剂。通过MS结合测定法筛选生成的化合物文库，这些文库基于动态组合化学中常用的化学，但具有假静态，可通过它们对mGAT1的结合亲和力进行筛选。用nipecotic酸衍生rac-16 h [rac-（3R，5S）-5-[（E）-2-[5-（2-苯基乙炔基）噻吩-2-基]亚甲基}肼} -1-基[哌啶-3-羧酸}-氯化钠（1/2）]，发现一个命中并评估显示出亚微摩尔效价（pKi = 6.62±0.04）和在mGAT1处的非竞争性相互作用模式。通过携带一个通过三原子间隔基连接到乳酸的5位上的5-（2-苯基乙炔基）噻吩-2-基残基，化合物rac-16 h包含了迄今为止对于这类生物活性分子而言空前的结构部分，并补充了在最近发表的一项筛选活动
• Development of a novel class of B-RafV600E-selective inhibitors through virtual screening and hierarchical hit optimization
  作者：Xiangqian Kong、Jie Qin、Zeng Li、Adina Vultur、Linjiang Tong、Enguang Feng、Geena Rajan、Shien Liu、Junyan Lu、Zhongjie Liang、Mingyue Zheng、Weiliang Zhu、Hualiang Jiang、Meenhard Herlyn、Hong Liu、Ronen Marmorstein、Cheng Luo

  DOI：10.1039/c2ob26081f

  日期：——

  Oncogenic mutations in critical nodes of cellular signaling pathways have been associated with tumorigenesis and progression. The B-Raf protein kinase, a key hub in the canonical MAPK signaling cascade, is mutated in a broad range of human cancers and especially in malignant melanoma. The most prevalent B-RafV600E mutant exhibits elevated kinase activity and results in constitutive activation of the MAPK pathway, thus making it a promising drug target for cancer therapy. Herein, we describe the development of novel B-RafV600E selective inhibitors via multi-step virtual screening and hierarchical hit optimization. Nine hit compounds with low micromolar IC50 values were identified as B-RafV600E inhibitors through virtual screening. Subsequent scaffold-based analogue searching and medicinal chemistry efforts significantly improved both the inhibitor potency and oncogene selectivity. In particular, compounds 22f and 22q possess nanomolar IC50 values with selectivity for B-RafV600Ein vitro and exclusive cytotoxicity against B-RafV600E harboring cancer cells.

  细胞信号通路关键节点的致癌突变与肿瘤的发生和发展有关。B-Raf蛋白激酶是典型MAPK信号级联的关键枢纽，在多种人类癌症，尤其是恶性黑色素瘤中发生突变。最常见的B-RafV600E突变体表现出较高的激酶活性，导致MAPK通路的组成性激活，从而使其成为一种很有希望的癌症治疗药物靶点。在此，我们介绍了通过多步虚拟筛选和分层命中优化开发新型 B-RafV600E 选择性抑制剂的情况。通过虚拟筛选，我们确定了九种具有低微摩尔 IC50 值的命中化合物作为 B-RafV600E 抑制剂。随后的基于支架的类似物搜索和药物化学工作显著提高了抑制剂的效力和对癌基因的选择性。其中，22f 和 22q 化合物的 IC50 值达到纳摩尔级，在体外对 B-RafV600E 具有选择性，对携带 B-RafV600E 的癌细胞具有独特的细胞毒性。
• Identification and Biochemical Characterization of Pyrrolidinediones as Novel Inhibitors of the Bacterial Enzyme MurA
  作者：Reem K. Fathalla、Wolfgang Fröhner、Chantal D. Bader、Patrick D. Fischer、Charlotte Dahlem、Deep Chatterjee、Sebastian Mathea、Alexandra K. Kiemer、Haribabu Arthanari、Rolf Müller、Mohammad Abdel-Halim、Christian Ducho、Matthias Engel

  DOI：10.1021/acs.jmedchem.2c01275

  日期：2022.11.10

  pyrrolidinedione-based MurA inhibitors that equally inhibit wild type (WT) MurA and the fosfomycin-resistant MurA C115D mutant, showing an additive effect with fosfomycin for the inhibition of WT MurA. For the most potent inhibitor 46 (IC50 = 4.5 μM), the mode of inhibition was analyzed using native mass spectrometry and protein NMR spectroscopy. The compound class was nontoxic against human cells and highly stable

  为了开发新型抗生素，针对细胞壁肽聚糖生物合成的早期步骤似乎是一种有前途的策略，但尚未得到充分利用。MurA 是该途径中的第一个酶，是临床使用的不可逆抑制剂磷霉素的靶标。然而，其结合位点的突变可能会导致细菌耐药性。我们在此报道了一系列新型可逆的基于吡咯烷二酮的 MurA 抑制剂，它们同样抑制野生型 (WT) MurA 和磷霉素抗性 MurA C115D 突变体，显示出磷霉素对 WT MurA 抑制的累加效应。对于最有效的抑制剂46 (IC 50 = 4.5 μM)，使用天然质谱和蛋白质 NMR 光谱分析了抑制模式。该化合物类对人体细胞无毒，并且在人 S9 级分、人血浆和细菌细胞裂解液中高度稳定。总而言之，这种新型化合物类别可能会进一步开发为抑制细胞壁合成的抗生素候选药物。